EA200300560A1 - Улучшенный способ лечения - Google Patents

Улучшенный способ лечения

Info

Publication number
EA200300560A1
EA200300560A1 EA200300560A EA200300560A EA200300560A1 EA 200300560 A1 EA200300560 A1 EA 200300560A1 EA 200300560 A EA200300560 A EA 200300560A EA 200300560 A EA200300560 A EA 200300560A EA 200300560 A1 EA200300560 A1 EA 200300560A1
Authority
EA
Eurasian Patent Office
Prior art keywords
visual impairment
treatment method
improved treatment
agents
suffer
Prior art date
Application number
EA200300560A
Other languages
English (en)
Inventor
Хелене Ричардсон
Том Дж. Циммерман
Тереза Чаллонер
Пер Йонссон
Анна Гренблад
Патрик Эхаген
Дональд Гизекер
Original Assignee
Фармация Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22937766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200300560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармация Аб filed Critical Фармация Аб
Publication of EA200300560A1 publication Critical patent/EA200300560A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Настоящее изобретение направлено на применение комбинации одного или более средств, способных снижать внутриглазное давление, которые обеспечивают улучшенную эффективность при лечении запущенной глаукомы у таких пациентов, которые страдают выявляемыми нарушениями зрения, при одновременном введении указанных средств. Комбинированное применение также будет иметь преимущество при лечении индивидуумов, нуждающихся в снижении высокого ВГД, таких, которые подвержены воздействию факторов риска, делающих их восприимчивыми к нарушениям зрения.Отчет о международном поиске был опубликован 2003.01.30.
EA200300560A 2000-11-13 2001-11-12 Улучшенный способ лечения EA200300560A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24812300P 2000-11-13 2000-11-13
PCT/SE2001/002499 WO2002038158A1 (en) 2000-11-13 2001-11-12 Improved treatment

Publications (1)

Publication Number Publication Date
EA200300560A1 true EA200300560A1 (ru) 2003-10-30

Family

ID=22937766

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300560A EA200300560A1 (ru) 2000-11-13 2001-11-12 Улучшенный способ лечения

Country Status (17)

Country Link
US (1) US20030018079A1 (ru)
EP (1) EP1333837A1 (ru)
JP (1) JP2004513148A (ru)
KR (1) KR20030068150A (ru)
CN (1) CN1233324C (ru)
AR (1) AR035541A1 (ru)
AU (1) AU2002215277A1 (ru)
BR (1) BR0115208A (ru)
CA (1) CA2426049A1 (ru)
EA (1) EA200300560A1 (ru)
HU (1) HUP0400548A3 (ru)
MX (1) MXPA03004183A (ru)
NO (1) NO20032122L (ru)
NZ (1) NZ525817A (ru)
PL (1) PL362855A1 (ru)
WO (1) WO2002038158A1 (ru)
ZA (1) ZA200303771B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
EP2241636A1 (en) * 2002-03-13 2010-10-20 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
DE60326226D1 (de) * 2002-03-21 2009-04-02 Cayman Chemical Co Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom
ES2382733T3 (es) 2002-08-29 2012-06-13 Santen Pharmaceutical Co., Ltd. Remedio para el glaucoma que comprende un inhibidor de la Rho quinasa y prostaglandinas
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
ES2444841T3 (es) * 2002-11-18 2014-02-27 Santen Pharmaceutical Co., Ltd. Remedio para el glaucoma que comprende inhibidor de Rho cinasa y beta-bloqueante
US20070093507A1 (en) * 2003-09-05 2007-04-26 Lambrou George N Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
AU2004313688B2 (en) 2004-01-05 2010-08-05 Nicox S.A. Prostaglandin nitrooxyderivatives
PL1759702T3 (pl) * 2004-05-26 2009-06-30 Bayardo Arturo Jimenez Sposób wytwarzania roztworu latanoprostu do oczu oraz roztwór otrzymany tym sposobem
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
WO2006137368A1 (ja) 2005-06-21 2006-12-28 Kowa Co., Ltd. 緑内障の予防又は治療剤
ES2416334T3 (es) 2005-07-12 2013-07-31 Kowa Company. Ltd. Agente para la prevención o el tratamiento del glaucoma
ITRM20080182A1 (it) 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
WO2010119305A1 (en) * 2009-04-14 2010-10-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of quaternary ammonium compounds in dissolving of latanoprost
CN102085175B (zh) * 2009-12-02 2013-01-30 沈阳兴齐眼药股份有限公司 一种眼用凝胶剂及其制备方法
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
CA2860453C (en) 2011-01-24 2020-04-28 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
TW201906614A (zh) 2011-02-04 2019-02-16 日商興和股份有限公司 青光眼或高眼壓症之預防或治療用之點眼藥
CN102389433A (zh) * 2011-11-04 2012-03-28 兆科药业(香港)有限公司 一种药物组合物及其复方制剂
KR20200103042A (ko) 2017-12-21 2020-09-01 산텐 세이야꾸 가부시키가이샤 세페타프로스트와 Rho 키나아제 저해제의 조합 의약
CN111491636A (zh) 2017-12-21 2020-08-04 参天制药株式会社 奥米帕格的组合

Also Published As

Publication number Publication date
JP2004513148A (ja) 2004-04-30
WO2002038158A8 (en) 2003-01-30
CA2426049A1 (en) 2002-05-16
BR0115208A (pt) 2003-10-07
EP1333837A1 (en) 2003-08-13
NO20032122D0 (no) 2003-05-12
HUP0400548A3 (en) 2007-05-29
MXPA03004183A (es) 2004-12-02
PL362855A1 (en) 2004-11-02
CN1233324C (zh) 2005-12-28
HUP0400548A2 (hu) 2004-06-28
KR20030068150A (ko) 2003-08-19
WO2002038158A1 (en) 2002-05-16
US20030018079A1 (en) 2003-01-23
NZ525817A (en) 2005-03-24
CN1473046A (zh) 2004-02-04
AU2002215277A1 (en) 2002-05-21
AR035541A1 (es) 2004-06-16
NO20032122L (no) 2003-07-01
ZA200303771B (en) 2004-05-17

Similar Documents

Publication Publication Date Title
EA200300560A1 (ru) Улучшенный способ лечения
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
ATE254461T1 (de) Behandlung von augenschmerzen
NO20033617L (no) Fremgangsmate for behandling av diabetes mellitus
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
SE9404196D0 (sv) New antithrombotic formulation
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2004004757A8 (en) Treatment for eye disorder
HK1020867A1 (en) The topical use of kappa opioid agonists to treat ocular pain k
EA201000386A1 (ru) Нетоксичные для нервной ткани плазминоген-активирующие факторы для лечения инсульта
DK1463563T3 (da) Superoxiddismutas-mimetika til behandling af öjenlidelser og -sygdomme
MXPA03005922A (es) Metodo para tratar glaucoma ib.
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES
ATE359774T1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
SE9403160D0 (sv) Method and means for prevention and treatment of secondary cataract
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
EP1365771A4 (en) METHOD OF TREATING CERTAIN EYE DISEASES
ATE344054T1 (de) Behandlung von okularen neovaskularen erkrankungen
WO2002015942A8 (en) Method for the identification of agents that inhibit or promote cataracts and uses thereof
BR0212991A (pt) Métodos de tratamento oftalmológico utilizando inibidores seletivos de inos
NO984190L (no) FremgangsmÕte for behandling av insomnia
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
UA37151A (ru) Способ лечения глаукомы и устройство для его осуществления
UA29333A (ru) Глазная мазь